Crinetics Pharmaceuticals, Inc.

NasdaqGS CRNX

Crinetics Pharmaceuticals, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -43.31%

Crinetics Pharmaceuticals, Inc. Gross Profit Margin is -43.31% for the Trailing 12 Months (TTM) ending September 30, 2024, a -162.64% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Crinetics Pharmaceuticals, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was 69.14%, a 16.59% change year over year.
Crinetics Pharmaceuticals, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was 59.30%, a 100.00% change year over year.
Crinetics Pharmaceuticals, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -25,022,535,211,267,508.00%, a -188,925,709,713,525.56% change year over year.
Crinetics Pharmaceuticals, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was -13,244.64%, a -519.14% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NasdaqGS: CRNX

Crinetics Pharmaceuticals, Inc.

CEO	Dr. R. Scott Struthers Ph.D.
IPO Date	July 18, 2018
Location	United States
Headquarters	Building No. 2
Employees	290
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Key trends

Past 5 years